Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 3, 2016, Pages 312-326

  Festic, Emir ^a   Bansal, Vikas ^a   Gupta, Ena ^b   Scanlon, Paul D ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

bias; case fatality; drop out; heterogeneity

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE; MOMETASONE FUROATE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; FATALITY; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; HUMANS; INCIDENCE; MORTALITY; OBSERVATIONAL STUDIES AS TOPIC; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84949210639     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2015.1081162     Document Type: Article

References (49)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the Global Strategy for the Diagnosis, Management and Prevention of COPD. 2011. Available from: Available at: http://www.goldcopd.org/ (accessed 31 March, 2015).
2. P.M.Calverley, J.A.Anderson, B.Celli, G.T.Ferguson, C.Jenkins, P.W.Jones, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775–789.
3. G.T.Ferguson, A.Anzueto, R.Fei, A.Emmett, K.Knobil, C.Kalberg. Effect of fluticasone propionate/salmeterol (250/50 mug) or salmeterol (50 mug) on COPD exacerbations. Respir Med 2008; 102(8): 1099–1108.
4. A.Anzueto, G.T.Ferguson, G.Feldman, K.Chinsky, A.Seibert, K.Knobil, Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6(5): 320–329.
5. P.M.Calverley, R.A.Stockley, T.A.Seemungal, G.Hagan, L.R.Willits, J.H.RIley, Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139(3): 505–512.
6. A.Sharafkhaneh, J.G.Southard, M.Goldman, T.Uryniak, U.J.Martin. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106(2): 257–268.
7. M.T.Dransfield, J.Bourbeau, P.W.Jones, N.Hanania, D.A.Mahler, J.Vestbo, Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1(3): 210–223.
8. E.Festic, Bansal, V.Gajic, O.Lee, A.S.United States Critical Illness, Injury Trials Group: Lung Injury Prevention Study. Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 2014; 89(2): 154–162.
9. P.Ernst, A.V.Gonzalez, P.Brassard, S.Suissa. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2): 162–166.
10. S.Singh, A.V.Amin, Y.K.Loke. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch Intern Med 2009; 169(3): 219–229.
11. D.Chen, M.I.Restrepo, M.J.Fine, M.J.Pugh, A.Anzeuto, M.L.Metersky, Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011; 184(3): 312–316.
12. R.M.de Molina, E.M.Mortensen, M.I.Restrepo, L.A.Copeland, M.J.V.Pugh, A.Anzueto. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36(4): 751–757.
13. A.Singanayagam, J.D.Chalmers, A.R.Akram, A.T.Hill. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38(1): 36–41.
14. J.Sellares, A.Lopez-Giraldo, C.Lucena, C.Cilloniz, R.Amaro, E.Poverino, Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013; 187(11): 1241–1248.
15. A.Liapikou, E.Polverino, S.Ewig, C.Cillóniz, M.A.Marcos, J.Mensa, Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012; 39(4): 855–861.
16. S.Singh, Y.K.Loke. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010; 16(2): 118–122.
17. S.D.Aaron, K.L.Vandemheen, D.Fergusson, J.Bourbeau, R.Goldstein, M.Balter, Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007; 146(8): 545–555.
18. P.M.Calverley, W.Boonsawat, Z.Cseke, N.Zhong, S.Peterson, H.Olsson. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6): 912–919.
19. P.Calverley, R.Pauwels, J.Vestbo, P.Jones, N.Pride, A.Gulsvik, Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449–456.
20. P.M.A.Calverley, P.Kuna, E.Monso, M.Costantini, S.Petruzzelli, F.Sergio, Beclomethasone/formoterol in the management of COPD: A randomised controlled trial. Respir Med 2010; 104(12): 1858–1868.
21. C.Crim, P.M.Calverley, J.A.Anderson, B.Celli, G.T.Ferguson, C.Jenkins, Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34(3): 641–647.
22. D.E.Doherty, D.P.Tashkin, E.Kerwin, B.A.Knorr, T.Shekar, S.Banerjee, Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): Results from a 52-week phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 57–71.
23. P.Kardos, M.Wencker, T.Glaab, C.Vogelmeier. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–149.
24. F.J.Martinez, J.Boscia, G.Feldman, C.Scott-Wilson, S.Kilbride, L.Fabbri, Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: A randomised trial. Respir Med 2013; 107(4): 550–559.
25. S.I.Rennard, D.P.Tashkin, J.McElhattan, M.Goldman, S.Ramachandran, U.J.Martin, Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69(5): 549–565.
26. D.P.Tashkin, D.E.Doherty, E.Kerwin, C.E.Matiz-Bueno, B.Knorr, T.Shekar, Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012; 7: 73–86.
27. D.P.Tashkin, S.I.Rennard, P.Martin, S.Ramachandran, U.J.Martin, P.E.Silkoff, M.Goldman. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68(14): 1975–2000.
28. J.Vestbo, T.Sorensen, P.Lange, A.Brix, P.Tone, K.Viskum. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353(9167): 1819—1823.
29. C.F.Vogelmeier, E.D.Bateman, J.Pallante, V.K.T.Alagappan, P.D'Andrea, H.Chen, Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): A randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1(1): 51–60.
30. P.S.Burge, P.M.A.Calverley, P.W.Jones, S.Spencer, J.A.Anderson, T.K.Maslen. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE Trial. BMJ 2000; 320(7245):1297–1303.
31. W.Szafranski, A.Cukier, A.Ramirez, G.Menga, R.Sansores, S.Nahabedian, Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(5):74–81.
32. R.A.Pauwels, C.G.Lofdahl, L.A.Laitinen, J.P.Schouten, D.S.Postma, N.B.Pride, S.V.Ohlsson. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948–1953.
33. P.L.Paggiaro, R.Dahle, I.Bakran, L.Frith, K.Hollingworth, J.Efthimiou. Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351(9105):773–780.
34. GlaxoSmithKline. Clinical study register. Study No. FLTA3025. Avaialble from: http://www.gskclinicalstudyregister.com/files/pdf/1231.pdf (accessed 29 January, 2015).
35. GlaxoSmithKline. Clinical study register. Study No.SCO100470. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/1079.pdf (accessed 29 January, 2015).
36. GlaxoSmithKline. Clinical study register. Study No.SCO40041. Available from: http://www.gsk-clinicalstudyregister.com/files/pdf/21086.pdf (accessed 29 January, 2015).
37. P.van der Valk, E.Monninkhof, J.van der Palen, G.Zielhuis, C.van Herwaarden. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE Study. Am J Respir Crit Care Med 2002; 166(10):1358–1363.
38. E.F.Wouters, D.S.Postma, B.Fokkens, W.C.Hop, J.Prins, A.F.Kuipers, for the COSMIC (COPD and Seretide; a Multicenter Intervention and Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60(6):480–487.
39. D.A.Mahler, P.Wire, D.Horstman, C.N.Chang, J.Yates, T.FIscher, T.Shah. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8):1084–1091.
40. E.Kerwin, C.Scott-Wilson, L.Sanford, S.Rennard, A.Agusti, N.Barnes, C.Crim. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 1–/25 μg) on lung function in COPD. Respir Med 2013; 107:560–569.
41. S.L.Cheng, H.C.Wang, S.J.Cheng, C.J.Yu. Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm 2011; 11: 46.
42. P.Ernst, S.Suissa. Pneumonia in elderly patients with chronic obstructive pulmonary disease. Curr Infect Dis Rep 2008; 10(3): 223–228.
43. M.J.Joo, D.H.Au, M.L.Fitzgibbon, T.A.Lee. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104(2): 246–52.
44. F.W.S.Ko, M.Ip, P.K.S.Chan, S.S.Ng, S.S.Chau, D.S.C.Hui. A one -year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomittant pneumonia. Respir Med 2008; 102:1109–1116.
45. D.M.G.Halpin, J.Gray, S.J.Edwards, J.Morais, D.Singh. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011; 65(7): 764–774.
46. O.Sibila, A.Anzueto, M.I.Restrepo. The paradoxical effect on pneumonia of chronic inhaled corticosteroids. Clin Pulm Med 2013; 20(1): 6–10.
47. A.Torres, O.Sibila, M.Ferrer, E.Polverino, R.Menendez, J.Mensa, Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response. JAMA 2015; 313(7):677–686.
48. E.Festic, P.Scanlon. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med 2015; 191(2):141–148
49. A.S.Gershon, M.A.Campitelli, R.Croxford, M.B.Stanbrook, T.To, R.Upshur, Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312(11):1114–1121.